Scott Rocklage has over three decades of healthcare management experience. Dr. Rocklage Ph.D., responsibilities has led to FDA approval of three U.S. New Drug Applications. Dr. Rocklage served as CEO of Cubist Pharmaceuticals and CEO of Nycomed Salutar. Dr. Rocklage earned his B.S. in Chemistry also his Ph.D. in Chemistry.
Scott Rocklage is an inventor of over 30 patents and 100 peer-reviewed publications. Dr. Rocklage Managing Partner at 5AM Venture Management LLC since 2004. Dr. Rocklage shows his gratitude by giving a major gift to the Chemistry Department that was the foundation of his professional career. Dr. Rocklage’s gift to assist with the cost of the renovation of Lester Wolfe Professor of Chemistry.
Currently Dr. Scott Rocklage serves as Board Chairman of Achaogen, Relypsa and Semprus as well as on the Boards of WaveRx, Pulmatrix and Variation. Dr. Rocklage’s strategic leadership has successfully created approved drugs and the reason his Board Membership list is long. Dr. Rocklage earned his degrees from the University of California Berkeley and Massachusetts Institute of Technology.
CEO of Nycomed Interventional, Inc., a medical device company. Dr. Rocklage is responsible for designing and implementing research and development programs that resulted in human clinical trails. Executive Chairman of Miikana, EntreMed and Llypsa. R&D position at Catalytica.
Other affiliations Protana Inc., Amersham Health, VBI Vaccines Inc., Therapeutics Inc., Novina Therapeutics, Inc., and Rennovia Inc. Dr. Rocklage at age 60 has been a huge impact on the medical field his knowledge has created break though medicines. Dr. Rocklage a mentor.